

SWISS BIOTECH SUCCESS STORY



Etienne Jornod

Etienne Jornod spent his entire career at Vifor-Galenica Group where he was Executive Chairman until early 2020.

Since October 2020, he is Executive Chairman and Co-Owner of OM Pharma.

VIFOR PHARMA Revolutionizing Iron Sucrose

The development of an injectable medication to treat iron deficiency anemia in patients with chronic kidney disease marked the beginning of Etienne Jornod's entrepreneurial success at Vifor Pharma.



Developing Ferric Carboxymaltose

This iron success was followed by the development of a novel iron complex, enabling controlled delivery of iron to target tissues throughout the body.

VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA

This Joint Venture with Fresenius-FMC, in which Etienne Jornod was extensively involved, resulted in the successful launch of Mircera® in the US in partnership with Roche, and has attracted new licensed products in the field of dialysis: Rayaldee®, Tavneos®, Kapruvia®, Vadadustat®.




Transitioning to OM Pharma

When Etienne Jornod decided to leave, Vifor-Galenica Group has been able to deliver 25 consecutive times a double-digit growth in net profit and increase the value of its share from CHF 3.40 to CHF 185.25, with a total value increasing from MCHF 220 to MCHF 1,200 from 1995 to 2019.

During his tenure, the company has improved the lives of millions of patients and created thousands of jobs.

Who is OM Pharma

OM Pharma is a global biopharmaceutical company, leader in the prevention of recurrent respiratory and urinary tract infections. In October 2020, Etienne Jornod bought it from Vifor Pharma with his friends.



Its leading products Broncho-Vaxom® and Uro-Vaxom® are bacterial lysates, composed respectively of 21 and 18 pathogen bacterial strains. Manufactured in Geneva, they are distributed in more than 100 countries across the world, via an established, international network of partners.



OM Pharma employs around 450 people globally and has a strong presence in Switzerland, with 350 people in Geneva (Global headquarters & biotech center).

The New OM Pharma's Vision

With the New OM Pharma project, Etienne Jornod aims to create a very innovative biopharmaceutical company based on the unique bacterial lysate expertise developed over decades by OM Pharma.

Encompassing seven projects, the goal of improving patients' lives is central to the development of new medicines for asthma, atopic dermatitis, wheezing and other diseases of the respiratory and urinary systems.



Knowledge & Research

High levels of biotech knowledge and experienced teams with substantial know-how in the manufacturing of immunomodulators based on active bacteria.


Innovative scientific research aiming at extending the use of bacterial lysates for the prevention and treatment of a wide range of immuno-inflammatory diseases, as well as development of new chemical entities.

Etienne Jornod's principles for the New OM Pharma

Trust is the basis of any collaboration, therefore of any project
Performance & Deliver what we promise creates trust
To succeed we must be honest, transparent and love people

SUCCESS CATEGORIES

- ★ Completed achievement with lasting impact
- ★ Product approval and sustainable revenues
- ★ Involvement of one or more Swiss citizen
- ★ Swiss-based company/institution
- ★ Creation of jobs in Switzerland
- ★ Other aspect with a direct link to Switzerland
- ★ Enabler for the biotech industry
- ★ Swissness: Think global, made in Switzerland



Organized by

